Effect of Tołpa Peat Preparation on Some Immune Parameters in Healthy Volunteers. Preliminary Data
Key Findings
- Healthy volunteers took oral Tołpa Peat Preparation (TPP) at 50, 100, 300, or 600 mg/day for 14 days, 4 volunteers per dose
- Measured T-lymphocyte subsets, IL-1/IL-2 generation, IL-2 receptor expression, lymphocyte proliferation, monocyte TNF-alpha, and granulocyte superoxide production
- Considerable differences were found at higher TPP doses across several immune parameters
- The authors themselves caveat the small group size (4 per dose) and absence of a placebo group as reasons to treat the results as preliminary
The first human-dosing study of oral Tołpa Peat Preparation (TPP) — a specific, standardized peat-derived preparation, not peat in general — testing four dose levels against a panel of immune markers. Higher doses produced notable shifts in several parameters, but with only four volunteers per dose group and no placebo arm, the authors explicitly frame their own results as preliminary rather than conclusive. Abstract-only sourcing; no full text was located.
Where this source is used on this site
Each page below cites this paper as evidence for a specific claim. The note shows what the page draws from it.
Human volunteers, oral TPP 50-600 mg/day x14 days: dose-dependent shifts in T-lymphocyte subsets, IL-1/IL-2, TNF-alpha, granulocyte superoxide — authors' own caveat: preliminary (n=4/dose, no placebo)